Access to clinical pharmacy services in a pharmacist-physician covisit model

Ulrich, Irene Park; Lugo, Brunilda; Hughes, Phillip; Doucette, Lorna; Creith, Bianca B.; Flanagan, Sean; Gilmer, Benjamin

doi:10.1016/j.sapharm.2020.10.002

Cited by 2 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Implementation of a clinical pharmacist in the primary care setting can offset some chronic disease state management using Collaborative Practice Agreements (CPAs), which may include HTN, DM, and hyperlipidemia (HLD). Pharmacist management of these conditions has been shown to have a positive impact on access to health care services and chronic disease state control in many settings 1 . Integrating a clinical pharmacist can expand provider availability to see new patients, provide follow-up for established patients, or manage complex diseases 1 .…”

Section: Introductionmentioning

confidence: 99%

“…Pharmacist management of these conditions has been shown to have a positive impact on access to health care services and chronic disease state control in many settings 1 . Integrating a clinical pharmacist can expand provider availability to see new patients, provide follow-up for established patients, or manage complex diseases 1 . The pharmacist-physician co-visit model allows a pharmacist and provider to see the patient within the same appointment and has been shown to create interprofessional collaboration and is more convenient for patients 8 .…”

Section: Introductionmentioning

confidence: 99%

“…The co-visit model not only reduces the burden placed on PCPs to manage chronic disease states and expands patient access, but also results in improved health outcomes, such as improvement in hemoglobin A1c in patients with type 2 DM 3,4 . Previous studies have found that the co-visit model generated 4924.41 dollars in additional income over 14 half-days, allowed providers to see, on average, 1.3 additional patients per half day compared to individual visits, and justified the addition of one full-time equivalent pharmacist position 1,2,9 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Improving Patient Access to Primary Care Providers Using a Pharmacist-Physician Co-Visit Model

Palandri¹,

Raber²,

Tak³

et al. 2023

Innov Pharm

View full text Add to dashboard Cite

Background: Implementation of a clinical pharmacist in the primary care setting can offset provider time spent managing chronic diseases using Collaborative Practice Agreements (CPAs). The pharmacist-physician co-visit model presents an opportunity for pharmacists to increase patient access to their primary care provider (PCP). Studies of the co-visit model show that co-visits increase clinic efficiency by allowing the PCP to see additional patients and achieve more health care goals compared with independent visits. Objectives: The aim of this study was to increase patient access to their PCP by utilizing a pharmacist-physician co-visit model at the Madsen Health Center Family Medicine (MHC FM) Clinic. The primary outcome was to identify the number of co-visits completed compared to the number of possible co-visits, and the number of appointment slots made available. The secondary outcomes were to track the time spent with patients and to obtain provider feedback via a survey. Methods: The co-visit model was implemented as a 4-month pilot study at the MHC FM Clinic. Complex care appointments lasting 40 minutes were selected based on inclusion and exclusion criteria. Potential co-visit appointments were identified one week prior then provider consent was obtained to change the appointment into two separate 20-minute visits. Schedules were reviewed to determine if the appointment slot opened by the co-visit was filled by another patient. Upon completion of the study, a survey was distributed to providers to collect feedback. Results: A total of five co-visits were completed out of a possible 19 (26%). All the appointments made available were filled by another patient. On average, the provider and pharmacist spent 15 and 14 minutes with the patient, respectively. Conclusion: Implementation of the physician-pharmacist co-visit model increased the availability of the PCP to see more patients without disrupting clinic workflow and provider schedules.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improving Patient Access to Primary Care Providers Using a Pharmacist-Physician Co-Visit Model

Palandri¹,

Raber²,

Tak³

et al. 2023

Innov Pharm

View full text Add to dashboard Cite

show abstract

Bridging the continuity: Practice-enhancing publications about the ambulatory care medication-use process in 2021

Gazda,

Vest,

Peek

et al. 2024

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose This article identifies, prioritizes, and summarizes published literature on the ambulatory care medication-use process (ACMUP) from calendar year 2021 that can impact ambulatory pharmacy practice. The MUP is the foundational system that provides the framework for safe medication utilization within the healthcare environment and was reimagined to focus on new innovations and advancements in ambulatory pharmacy practice. The ACMUP is defined in this article as having the following components: transitions of care, prescribing and collaborative practice, accessing care, adherence, and monitoring and quality. Articles evaluating at least one step of the ACMUP were assessed for their usefulness toward practice improvement. Summary A PubMed search was conducted in January 2022 for the year 2021 using targeted Medical Subject Headings keywords and the tables of contents of selected pharmacy journals were also searched, providing a total of 6,026 articles. A thorough review identified 86 potentially practice-enhancing articles: 10 for transitions of care, 9 for prescribing and collaborative practice, 20 for adherence, 17 for accessing care, 18 for monitoring and quality, and 12 for monitoring and medication therapy management. Ranking of the articles for importance by peers led to the selection of key articles from each category. The highest ranked articles are briefly summarized, with a mention of why each article is important. The other articles are listed for further review and evaluation. Conclusion It is important to routinely review the published literature and to incorporate significant findings into daily practice. This article continues a series of articles defining and evaluating the currently published literature around the ACMUP. As healthcare continues to advance and care shifts to ambulatory settings, the ACMUP will continue to be a crucial process to evaluate.

show abstract

Access to clinical pharmacy services in a pharmacist-physician covisit model

Cited by 2 publications

References 23 publications

Improving Patient Access to Primary Care Providers Using a Pharmacist-Physician Co-Visit Model

Improving Patient Access to Primary Care Providers Using a Pharmacist-Physician Co-Visit Model

Bridging the continuity: Practice-enhancing publications about the ambulatory care medication-use process in 2021

Contact Info

Product

Resources

About